ZA200508086B - Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections - Google Patents
Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infectionsInfo
- Publication number
- ZA200508086B ZA200508086B ZA200508086A ZA200508086A ZA200508086B ZA 200508086 B ZA200508086 B ZA 200508086B ZA 200508086 A ZA200508086 A ZA 200508086A ZA 200508086 A ZA200508086 A ZA 200508086A ZA 200508086 B ZA200508086 B ZA 200508086B
- Authority
- ZA
- South Africa
- Prior art keywords
- polysaccharide
- carrier protein
- protein conjugates
- immunization against
- nosocomial infections
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 title 1
- 108010078791 Carrier Proteins Proteins 0.000 title 1
- 206010011409 Cross infection Diseases 0.000 title 1
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 title 1
- 230000003053 immunization Effects 0.000 title 1
- 238000002649 immunization Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45272803P | 2003-03-07 | 2003-03-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200508086B true ZA200508086B (en) | 2010-04-28 |
Family
ID=32990675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200508086A ZA200508086B (en) | 2003-03-07 | 2005-10-06 | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
Country Status (12)
Country | Link |
---|---|
US (2) | US9296795B2 (xx) |
EP (1) | EP1601381A2 (xx) |
JP (2) | JP5102487B2 (xx) |
KR (1) | KR20060035581A (xx) |
CN (2) | CN1787839B (xx) |
AU (1) | AU2004220590B2 (xx) |
BR (1) | BRPI0408167B1 (xx) |
CA (1) | CA2517439C (xx) |
MX (1) | MXPA05009351A (xx) |
NZ (1) | NZ561879A (xx) |
WO (1) | WO2004080490A2 (xx) |
ZA (1) | ZA200508086B (xx) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1565478B1 (en) | 2002-11-12 | 2017-08-02 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
JP4764830B2 (ja) * | 2003-12-17 | 2011-09-07 | ワイス・エルエルシー | 免疫原性ペプチド担体コンジュゲートおよびその生産法 |
EP2460813A1 (en) * | 2003-12-17 | 2012-06-06 | Janssen Alzheimer Immunotherapy | A beta immunogenic peptide carrier conjugates and methods of producing same |
EP1804833A2 (en) * | 2004-09-22 | 2007-07-11 | GlaxoSmithKline Biologicals SA | Staphylococcal immunogenic compositions |
FR2884830A1 (fr) | 2005-04-25 | 2006-10-27 | Sanofi Pasteur Sa | Procede de production de souches de staphylococcus aureus surproductrices |
GB0526038D0 (en) * | 2005-12-21 | 2006-02-01 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2476433A1 (en) * | 2006-03-30 | 2012-07-18 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
AR060188A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Procedimiento de conjugacion |
PE20120262A1 (es) * | 2006-03-30 | 2012-03-30 | Glaxosmithkline Biolog Sa | Procedimiento para la preparacion de inmunoconjugados que comprenden polisacarido u oligosacarido capsular de s. aureus junto con la proteina portadora |
FR2899110A1 (fr) | 2006-03-31 | 2007-10-05 | Sanofi Pasteur Sa | Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus |
KR100829257B1 (ko) * | 2006-06-22 | 2008-05-14 | 부경대학교 산학협력단 | 인간 섬유육종세포에서 메트릭스 메탈로프로테이나제-9의발현 및 활성을 억제하는 카복시화 글루코사민 화합물 및이를 함유한 메트릭스 메탈로프로테이나제-9 억제제 |
KR100780868B1 (ko) | 2006-07-10 | 2007-11-30 | 부경대학교 산학협력단 | 항암효과를 나타내는 4급 아미노 글루코사민 화합물 |
GB0700136D0 (en) * | 2007-01-04 | 2007-02-14 | Glaxosmithkline Biolog Sa | Process for manufacturing vaccines |
EP2666784B1 (en) * | 2007-08-31 | 2017-04-05 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
WO2009127677A1 (en) * | 2008-04-16 | 2009-10-22 | Glaxosmithkline Biologicals S.A. | Vaccine |
DK2315747T3 (en) | 2008-07-21 | 2018-02-26 | Brigham & Womens Hospital Inc | Methods and Compositions of Synthetic Beta-1.6 Glucosamine Oligosaccharides |
US9125951B2 (en) * | 2009-06-22 | 2015-09-08 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
SI2445522T1 (sl) | 2009-06-22 | 2017-10-30 | Wyeth Llc | Imunogeni sestavki antigenov Staphylococcusa aureusa |
NZ616921A (en) | 2009-07-15 | 2015-06-26 | Genentech Inc | Gram-positive bacteria specific binding compounds |
GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2013506651A (ja) | 2009-09-30 | 2013-02-28 | ノバルティス アーゲー | Staphylococcus.aureus5型および8型莢膜多糖の結合体 |
PL2493498T3 (pl) | 2009-10-30 | 2017-08-31 | Glaxosmithkline Biologicals Sa | Oczyszczanie sacharydów otoczkowych staphylococcus aureus typu 5 i typu 8 |
CA2819120C (en) | 2010-12-22 | 2016-07-05 | Wyeth Llc | Stable immunogenic compositions of staphylococcus aureus antigens |
CN102759618A (zh) * | 2012-07-18 | 2012-10-31 | 成都欧林生物科技股份有限公司 | 用ELISA法检测血清中Hib多糖抗体含量的方法 |
MX363511B (es) | 2012-08-16 | 2019-03-26 | Pfizer | Proceso de glucoconjugación y composiciones. |
HRP20221438T1 (hr) | 2012-12-20 | 2023-02-03 | Pfizer Inc. | Postupak glikokonjugiranja |
GB201310008D0 (en) | 2013-06-05 | 2013-07-17 | Glaxosmithkline Biolog Sa | Immunogenic composition for use in therapy |
DK3010535T3 (da) * | 2013-06-19 | 2020-11-30 | Integrated Biotherapeutics Inc | Toxoide peptider afledt fra fenol opløselige modulin, delta toxin, superantigener og fusioner deraf |
JP2016540764A (ja) * | 2013-12-04 | 2016-12-28 | グリコヴァキシン アーゲー | 大腸菌で合成された糖タンパク質ワクチンによる黄色ブドウ球菌感染の予防 |
US10668164B2 (en) | 2014-02-14 | 2020-06-02 | Pfizer Inc. | Immunogenic glycoprotein conjugates |
MX2017007652A (es) | 2014-12-10 | 2017-10-11 | Glaxosmithkline Biologicals Sa | Metodo de tratamiento. |
EP3292146A1 (en) | 2015-05-04 | 2018-03-14 | Pfizer Inc | Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof |
US11446371B2 (en) | 2015-11-05 | 2022-09-20 | The Texas A&M University System | Targeting of ligand binding sites in ClfA |
CN106084037B (zh) * | 2016-06-08 | 2020-01-07 | 中国人民解放军第二军医大学 | 一种炭疽杆菌荚膜表面三糖缀合物及其制备方法和应用 |
CN106366163A (zh) * | 2016-10-31 | 2017-02-01 | 中国人民解放军第二军医大学 | 一种β‑1,2‑D‑寡聚甘露糖肽‑蛋白缀合物及其制备方法和应用 |
TW201925222A (zh) * | 2017-06-23 | 2019-07-01 | 美商醫院疫苗公司 | 免疫原性組成物 |
CA3069747A1 (en) | 2017-07-27 | 2019-01-31 | Mohammad Javad Aman | Immunogenic composition comprising a fusion peptide derived from superantigen toxoids |
CN110484773B (zh) * | 2019-09-12 | 2020-06-23 | 江苏沃钛有色金属有限公司 | 一种钛合金基材及其制备方法 |
JP2023526780A (ja) | 2020-05-01 | 2023-06-23 | 神州細胞工程有限公司 | タンパク質/ペプチド抗原の免疫原性を向上させる方法 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189015A (en) | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
SE454403B (sv) | 1984-05-30 | 1988-05-02 | Alfa Laval Agri Int | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
IL78775A (en) * | 1985-05-15 | 1992-06-21 | Biotech Australia Pty Ltd | Oral vaccines |
US5571514A (en) | 1987-06-01 | 1996-11-05 | Alfa Laval Ab | Fibronectin binding protein as well as its preparation |
US5320951A (en) | 1987-06-01 | 1994-06-14 | Hoeoek Magnus | Fibronectin binding protein as well as its preparation |
SE8801894D0 (sv) | 1988-05-20 | 1988-05-20 | Alfa Laval Agri Int | Fibronektinbindande protein |
SE8901687D0 (sv) | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
US5440014A (en) | 1990-08-10 | 1995-08-08 | H+E,Uml/Oo/ K; Magnus | Fibronectin binding peptide |
US5851794A (en) | 1990-10-22 | 1998-12-22 | Alfa Laval Ab | Collagen binding protein as well as its preparation |
US5980908A (en) | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
US20020173462A1 (en) * | 1992-09-21 | 2002-11-21 | Boden Wastfelt Maria K. | Fibrinogen binding protein |
IL107458A0 (en) * | 1992-11-02 | 1994-02-27 | Gen Hospital Corp | Conjugate vaccine against group b streptococcus |
ATE254475T1 (de) | 1993-09-22 | 2003-12-15 | Jackson H M Found Military Med | Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten |
US5648240A (en) | 1994-05-24 | 1997-07-15 | Texas A&M University | MHC II analog from Staphylococcus aureus |
US6008341A (en) | 1994-08-22 | 1999-12-28 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
US6994855B1 (en) | 1994-08-22 | 2006-02-07 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | S. aureus fibrinogen binding protein gene |
CA2255669A1 (en) | 1996-05-16 | 1997-11-20 | The Texas A & M University System | Collagen binding protein compositions and methods of use |
SE9602496D0 (sv) | 1996-06-20 | 1996-06-20 | Bengt Guss | Method and means for producing a fibrinogen binding protein and its use in biotechnology |
WO1999003871A1 (en) * | 1997-07-17 | 1999-01-28 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hexadecasaccharide-protein conjugate vaccine for shigella dysenteriae type 1 |
US7252828B2 (en) * | 1998-07-15 | 2007-08-07 | The Brigham And Women's Hospital, Inc. | Polysaccharide vaccine for staphylococcal infections |
WO2000012689A1 (en) | 1998-08-31 | 2000-03-09 | The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Polypeptides and polynucleotides from coagulase-negative staphylococci |
ATE422368T1 (de) * | 1998-08-31 | 2009-02-15 | Inhibitex Inc | Multikomponenten impfstoffe gegen staphylococcus aureus |
US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
AU5408099A (en) | 1998-09-01 | 2000-03-21 | John F. Wetling | Electrically treated composition and use thereof |
EP1034792A1 (en) * | 1999-03-11 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Intranasal delivery of pneumococcal polysaccharide vaccines |
EP1035137A1 (en) * | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
JP4846906B2 (ja) * | 1999-03-19 | 2011-12-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | ワクチン |
WO2000071585A1 (en) * | 1999-05-03 | 2000-11-30 | Medarex, Inc. | Human antibodies to staphylococcus aureus |
DE19937864C2 (de) * | 1999-08-13 | 2002-10-31 | Rudolf Marx | Werkstück und Verfahren zum Herstellen und zum Verwerten des Werkstückes |
EP2298736B1 (en) * | 2000-03-22 | 2015-07-15 | Solulink, Inc. | Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
GB0007432D0 (en) * | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
MXPA03006561A (es) | 2001-01-23 | 2004-10-15 | Aventis Pasteur | Vacuna del conjugado proteina-polisacarido meningococico, multivalente. |
EP2339344A1 (en) | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
CA2351018A1 (en) * | 2001-07-09 | 2003-01-09 | Universite De Sherbrooke | Dna vaccine against staphylococcus aureus |
US20030113350A1 (en) * | 2001-09-19 | 2003-06-19 | Fattom Ali I. | Glycoconjugate vaccines for use in immune-compromised populations |
JP2005536185A (ja) | 2002-03-05 | 2005-12-02 | インヒビテックス インコーポレーテッド | コアグラーゼ陰性ブドウ球菌タンパク質を認識するモノクローナルおよびポリクローナル抗体 |
NZ561879A (en) | 2003-03-07 | 2009-05-31 | Wyeth Corp | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
US7892563B2 (en) | 2003-05-20 | 2011-02-22 | Wyeth Holdings Corporation | Methods for treatment of severe acute respiratory syndrome (SARS) |
-
2004
- 2004-03-04 NZ NZ561879A patent/NZ561879A/en not_active IP Right Cessation
- 2004-03-04 US US10/548,507 patent/US9296795B2/en active Active
- 2004-03-04 CN CN2004800122658A patent/CN1787839B/zh not_active Expired - Fee Related
- 2004-03-04 KR KR1020057016646A patent/KR20060035581A/ko not_active Application Discontinuation
- 2004-03-04 CN CN201110225310.XA patent/CN102366630B/zh not_active Expired - Fee Related
- 2004-03-04 MX MXPA05009351A patent/MXPA05009351A/es active IP Right Grant
- 2004-03-04 AU AU2004220590A patent/AU2004220590B2/en not_active Ceased
- 2004-03-04 EP EP04717417A patent/EP1601381A2/en not_active Withdrawn
- 2004-03-04 WO PCT/US2004/006661 patent/WO2004080490A2/en active Application Filing
- 2004-03-04 JP JP2006509140A patent/JP5102487B2/ja not_active Expired - Fee Related
- 2004-03-04 CA CA2517439A patent/CA2517439C/en not_active Expired - Fee Related
- 2004-03-04 BR BRPI0408167-6B1A patent/BRPI0408167B1/pt not_active IP Right Cessation
-
2005
- 2005-10-06 ZA ZA200508086A patent/ZA200508086B/xx unknown
-
2006
- 2006-11-07 US US11/593,481 patent/US8377451B2/en active Active
-
2011
- 2011-10-18 JP JP2011228995A patent/JP5757841B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2012051922A (ja) | 2012-03-15 |
AU2004220590A1 (en) | 2004-09-23 |
CN102366630A (zh) | 2012-03-07 |
JP5102487B2 (ja) | 2012-12-19 |
MXPA05009351A (es) | 2006-03-08 |
US20070087014A1 (en) | 2007-04-19 |
CA2517439C (en) | 2013-07-23 |
BRPI0408167A (pt) | 2006-03-21 |
US20070141077A1 (en) | 2007-06-21 |
KR20060035581A (ko) | 2006-04-26 |
CN102366630B (zh) | 2015-04-01 |
JP5757841B2 (ja) | 2015-08-05 |
CA2517439A1 (en) | 2004-09-23 |
WO2004080490A3 (en) | 2004-10-28 |
US8377451B2 (en) | 2013-02-19 |
EP1601381A2 (en) | 2005-12-07 |
AU2004220590B2 (en) | 2010-02-18 |
JP2006519870A (ja) | 2006-08-31 |
CN1787839B (zh) | 2011-09-28 |
CN1787839A (zh) | 2006-06-14 |
NZ561879A (en) | 2009-05-31 |
WO2004080490A2 (en) | 2004-09-23 |
US9296795B2 (en) | 2016-03-29 |
BRPI0408167B1 (pt) | 2014-10-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200508086B (en) | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections | |
IL243914A0 (en) | Antibodies against vegf | |
IL175710A0 (en) | Anti-mpl antibody | |
HK1213007A1 (zh) | 抗α 抗體 | |
PT1599504E (pt) | Anticorpo modificado | |
EP1648512A4 (en) | ANTI-CD19 ANTIBODIES | |
IL175608A0 (en) | Antibodies | |
SG135191A1 (en) | Biosensor | |
HK1084958A1 (en) | S. pneumoniae antigens | |
GB0308988D0 (en) | Molecule | |
ZA200307365B (en) | Antibodies specific for CD44V6. | |
EP1701948A4 (en) | ASSAY FOR DETECTOGEN | |
EP1598368A4 (en) | ANTI-PCI neutralizing ANTIBODY | |
EP1594888A4 (en) | TOLERANCE-INDUCED TARGET PRODUCTION OF ANTIBODIES | |
GB0301433D0 (en) | Protein adjuvant | |
MX263097B (es) | Inhibidores de entrada a moleculas pequenas. | |
IL163580A0 (en) | Assay for anti-ingap antibodies | |
GB0306618D0 (en) | Antibody | |
EP1556499A4 (en) | FOR CARCINOGENIC BACTERIA SPECIFIC MONOCLONAL ANTIBODIES | |
GB2407937B (en) | Position locating system | |
GB2407249B (en) | Yoghurt processing | |
HK1209139A1 (en) | Modified antibody | |
GB0311146D0 (en) | Small molecule biosensor | |
EP1701949A4 (en) | TEST OF ENTACTOGENES | |
GB0317974D0 (en) | Novel antibodies |